ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades


Among the companies with shares expected to actively trade in Wednesday's session are Vivus Inc. (VVUS), EMC Corp. (EMC) and VMWare Inc. (VMW). The U.S. Food and Drug Administration late Tuesday approved Vivus's weight-loss drug Qsymia, marking the second approval of a new weight-loss drug in less than a month. The agency in June approved a drug called Belviq, marketed by Arena Pharmaceuticals Inc. (ARNA). Cowen analysts say the debate now shifts to whether Qsymia or Belviq will sell better. "There is room for at least two, if not more, sizable drugs in the space. However, we believe that Qsymia has a significant advantage over Belviq given its considerably better efficacy," analysts wrote. Vivus shares surged 19% to $31.42 in premarket trade; Arena shares fell 8.1% to $10.15. Orexigen Therapeutics Inc. (OREX)--which is aiming to bring a diet drug to market--added 3.4% to $7.38. EMC moved forward its succession plans for Chief Executive Joe Tucci by naming a top executive to run VMware, a company it controls, as both companies gave strong preliminary revenue views for the second quarter. EMC shares jumped 6% to $24.30 premarket while VMware shares were up 5.9% to $85.05. Stanley Black & Decker Inc.'s (SWK) second-quarter earnings tumbled 22% as the tool maker's results came in lower than expected and the company unveiled additional cost-saving measures and lowered its full-year guidance. Shares were down 3.7% to $57.50 in premarket trade. Bank of America Corp. (BAC) swung to a second-quarter profit as the banking giant recorded double-digital revenue growth and benefited from a tough year-ago period when it took a hit from soured mortgages. Shares were last trading 1.1% higher at $8.01 premarket. Sally Beauty Holdings Inc. (SBH) said its largest shareholder--private equity firm Clayton, Dubilier & Rice LLC--plans to sell its stake by offering 23.1 million shares of the seller and distributor of professional beauty supplies. Shares of the company slid 8.8% to $24.71 premarket as it also reported preliminary third-quarter revenue that missed analyst expectations. Shares of Infinity Pharmaceuticals Inc. (INFI) slumped after the company said it had a restructured a pact with two strategic partners that will see it regain development and commercialization rights to all of its drug programs. Infinity in 2008 entered into an alliance with Purdue Pharmaceutical Products LP and Mundipharma International Corp. that was expected to help the company to expand its pipeline for cancer-fighting treatments. Under termination of the agreement disclosed Wednesday, Mundipharma will no longer provide research-and-development funding to Infinity. Infinity also Wednesday said it will issue 5.4 million of its shares as part of an equity investment being made by Purdue and to repay debt. Shares were down 11.5% to $13 premarket. Rovi Corp. (ROVI) projected fiscal second-quarter earnings below analyst expectations on weaker revenue from its consumer-electronics business, as the entertainment-data and technology company also cut its full-year view, citing delays in adding new patent licensees and the launches of certain products. Shares sank 26% to $13.12 premarket. Horizon Technology Finance Corp. (HRZN) will offer about 1.7 million shares of its common stock as the business-development company looks to repay debt. Shares were down 3.8% to $16.20 premarket. SS&C Technologies Holdings Inc. (SSNC) said its largest stakeholder, private-equity firm Carlyle Group LP (CG), will offer 7 million shares of the financial-software company's common stock, about 9% of total shares outstanding. Shares fell 6.3% to $24.30 premarket. Watchlist: AAR Corp.'s (AIR) fiscal fourth-quarter earnings fell 40% as the aircraft leasing and maintenance company logged heavy charges, resulting from restructuring and an adjustment to a defense contract. Abbott Laboratories's (ABT) second-quarter earnings fell 11% as restructuring and integration charges continued to mask the health-care company's revenue growth. Albemarle Corp.'s (ALB) second-quarter earnings slipped 67% as restructuring charges weighed on the specialty-chemicals maker's bottom-line results and as revenue grew less than expected. American Capital Agency Corp. (AGNC) said it plans to offer 32 million shares to raise funds to acquire additional agency securities and for general corporate purposes. American Safety Insurance Holdings Ltd. (ASI) sees second-quarter earnings falling far short of Wall Street expectations, as the reinsurer expects charges resulting from U.S. hail storms. Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline PLC (GSK, GSK.LN) said they are expanding their collaboration to develop a treatment for Fabry disease, with Glaxo agreeing to buy a larger stake in the smaller pharmaceutical company. Books-A-Million Inc. (BAMM) said its chairman and his family have withdrawn their contentious bid to buy out the company. CareFusion Corp. (CFN) issued another urgent recall on its EnVe ventilators last month, citing a potential leak in the patient breathing circuit or the system. CSX Corp. (CSX) reported a 1.2% uptick in second-quarter earnings despite a big drop in the volume of coal the railroad hauled to electric utilities, as expense controls and higher shipments of automobiles and containerized freight buoyed results. DirecTV Group Inc. (DTV) said it is getting closer to resolving its fee dispute with Viacom Inc. (VIA, VIAB) and said it keeps asking the operator of cable-television channels to return its networks as details are finalized. FIS Inc.'s (FIS) second-quarter earnings rose 22% as the payment- and bank-processing services company posted stronger revenue, led by growth in its financial segment. Adjusted earnings topped expectations. Harte-Hanks Inc. (HHS) projected second-quarter earnings and revenue below analyst expectations, noting weaker direct marketing revenue from its high tech, pharmaceutical and financial services customers. Honeywell International Inc.'s (HON) second-quarter profit rose 11% as the company's sales edged up, particularly in its aerospace unit. Intel Corp. (INTC) cut its full-year guidance and provided a soft outlook for the current period as a tough economic environment and consumer caution weigh on PC sales. Moody's Investors Service lowered Kinder Morgan Inc. (KMI) a notch further into junk territory, based on its recent acquisition of El Paso Corp. The U.S. Food and Drug Administration approved Vivus Inc.'s (VVUS) weight-loss drug Qsymia Tuesday, marking the second approval of a new weight-loss drug in less than a month. Wynn Resorts Ltd.'s (WYNN) second-quarter profit rose 13% but the casino operator's results fell short of analyst expectations. Yahoo Inc.'s (YHOO) second-quarter profit shrank 4.4% as the online-media company saw restructuring charges weigh down its results, though contributions from its Asian assets continued to grow. Write to Mia Lamar at Subscribe to WSJ:

Stock News for Arena (ARNA)
11/24/201508:00:00Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual...
11/19/201508:00:00Arena Pharmaceuticals to Host Analyst & Investor Day on December...
11/12/201511:00:033 Dangerous Stocks
11/10/201516:20:28Current Report Filing (8-k)
11/10/201516:00:00Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results...
11/09/201516:53:33Quarterly Report (10-q)
11/06/201512:20:29Why Orexigen Therapeutics, Inc.'s Stock Is Losing Weight Today
11/04/201508:00:00Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results...
11/02/201508:00:00Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin...
11/02/201507:04:023 Things You Never Knew About Medicare
10/30/201512:25:20Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
10/29/201516:36:00Current Report Filing (8-k)
10/29/201508:00:00Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of...
10/27/201516:14:37Current Report Filing (8-k)
10/27/201516:00:00Arena Pharmaceuticals Announces New Strategic Focus and Cost...
10/27/201508:00:00Arena Pharmaceuticals Issued Additional Patent Covering BELVIQ®...
10/26/201506:24:42Vivus: Qsymia Takes Second Place This Week- Is It A Sign?
10/26/201506:18:58Orexigen: Contrave Sales Flat- Big Bump In Market Share
10/26/201506:15:38Arena: Belviq Sales Drop To Third Place- Can A Turnaround Happen?
10/19/201515:44:00IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations